Clinical Laboratory Service Market Size, Share & Trends Analysis Report By Test Type (Human & Tumor Genetics, Clinical Chemistry), By Service Provider (Standalone, Hospital-based Labs), By Application, And Segment Forecasts, 2022 - 2030

Report Overview

The global clinical laboratory service market size was estimated at USD 201.94 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 3.7% from 2022 to 2030. The industry is witnessing growth due to factors, such increasing burden of chronic diseases and the growing demand for early diagnostic tests. Moreover, rapid advancements in data management and sample preparation due to the growing volumes of testing samples are anticipated to boost industry growth during the forecast period. However, there was a decrease in routine testing during the first quarter of 2021 due to the lockdown, but the industry has gradually begun to witness growth owing to increased testing volume for COVID-19. There was a gradual increase in the number of people suffering from COVID-19.

This has significantly alarmed the need for rapid testing. For instance, as of February 2022, there were around 392 million confirmed cases and 5.7 million deaths reported globally. Clinical laboratory services are extensively used for the detection and quantification of various substances. Changes in biomolecule concentration serve as an indication for various abnormal metabolic activities, infections, infectious & noninfectious diseases, and inflammatory conditions. The main elements that support ideal clinical outcomes and general public health include rapid & accurate diagnosis of serious diseases and their proper treatment. The use of at-home testing is increasing for the diagnosis of diseases & monitoring health conditions regularly.

However, the adoption of at-home testing is expected to hamper the industry growth in the forecast period. Advancements in technology, such as microfluidic circuits, have enabled people to diagnose themselves at home. For instance, in December 2021, to test for COVID-19 at home, two new OTC tests were approved & received EUA. However, the regulatory framework for approvals has always posed major restraints on the growth rate of the pharmaceutical, biotechnology, and medical technology industries. In the U.S., usage and safety profiles of laboratory tests & services are highly regulated and evaluated by the federal government through the Clinical Laboratory Improvement Amendments (CLIA). In 2020, Medicare part B spending reached USD 9.2 billion, which aided the industry flourish during the pandemic.

Test Type Insights

The clinical chemistry segment accounted for the largest revenue share of more than 54.00% in 2021. The dominance of the segment is attributed to the presence of numerous clinical chemistry tests involved in the pathology analysis of body fluids, including analysis of urine, plasma, serum, and other body fluids. For instance, in July 2022, EDAN Instruments, Inc. launched a next-generation ABG solution designed to reduce the burden in a patient care setting. Clinical chemistry tests form an integral part of basic-level diagnosis and laboratory testing. Techniques, such as spectrophotometry, immunoassay, and electrophoresis, are used to measure the concentration of different types of molecules present in the collected sample.

Increasing automation to enhance customer experience is gaining traction in the segment. The human & tumor genetics tests segment is expected to register the fastest CAGR during the forecast period. This can be attributed to a rise in intensive research activities on genetic & proteomic studies, in the context of hereditary & gene-mutation-related disorders. Moreover, there is an increasing demand for personalized care with accurate and early diagnosis in oncology. This is expected to fuel the segment's growth. For instance, in March 2022, Illumina Inc. launched TruSight oncology, a single test that can determine the precise genetic makeup of a patient’s cancer by evaluating various tumor genes and biomarkers.

Service Provider Insights

The hospital-based laboratories segment held the largest revenue share of more than 54.20 in 2021 and is expected to grow at the fastest CAGR over the forecast period. This is attributed to the high turnaround number of patients’ tests majorly for complex and severe disease conditions that are comparatively more cost-intensive. It is expected to maintain its dominance owing to the increasing number of hospitals integrating laboratories into their premises. The growing number of outreach programs by hospitals, coupled with the high turnaround of patients suffering from complex and major diseases, is expected to drive the segment. For instance, in October 2022, Quest Diagnostics announced buying a share of Summa Health’s outreach laboratory services commercial in an all-cash agreement.

This would help in increasing patient access to laboratory services. The standalone laboratories segment is expected to show a lucrative CAGR over the forecast period due to efforts to improve patient outcomes by providing diagnostic facilities at the retail level. The Center for Breakthrough Medicines (CBM) consists of a stand-alone safety testing facility separate from GMP activities on one campus. Moreover, the ability of standalone labs to handle large volumes of diagnostic tests at an expedited rate and provide better results at comparatively lower prices is likely to offer economies of scale to service providers. There has been rapid growth in the standalone market since COVID-19. Emerging players providing standalone clinical lab services are also expected to make a significant contribution to the segment's growth.

Application Insights

The bioanalytical & lab chemistry services segment accounted for the largest revenue share of more than 51.50% in 2021. Bioanalytical & lab chemistry laboratories use a wide range of techniques and technology platforms to fulfill diagnostic needs. ELISA, chromatography, immunochemistry, mass spectroscopy, and molecular biology are the most commonly used technologies in bioanalytical & lab chemistry applications. Bioanalytical services are an essential tool in drug discovery and development for determining the concentration of drugs and their metabolites. For instance, in November 2021, Labcorp launched a bioanalytical laboratory in Singapore expanding its bioanalytical presence in Asia Pacific.

The toxicology testing services segment is expected to register the fastest growth rate from 2022 to 2030. Toxicology testing services include the identification of chemicals, drugs, and other toxic elements that affect patients and help clinicians in predicting future toxic effects, confirming a different diagnosis, or guiding a therapy. For instance, in August 2022, LifeNet Health LifeSciences launched a human-relevant cell-based assay service by the acquisition of IONTOX, aiding in cytotoxic screening, biocompatibility assay, and a next-generation multi-organ platform. The main services in toxicity testing include urine testing, hair testing, blood testing, and saliva testing.

Regional Insights

Asia Pacific is expected to be the fastest-growing regional market at a CAGR of 5.4% during the forecast period. The rapid growth can be attributed to the various scientific research activities, high unmet medical needs, economic growth, and an improving healthcare regulatory scenario. Moreover, positive changes related to healthcare benefits, increasing awareness among the population, and availability of high-end medical treatments are projected to support the region’s growth. Clinical laboratories have gained immense importance during the COVID-19 pandemic owing to the increasing demand for testing. Key players are focusing on collaborations for providing new lab testing services.

For instance, in March 2022, GC Labs entered into a service agreement with Bio Lab in Bahrain and Biotrust in Cambodia, expanding its presence in Asia & Middle East. North America is also estimated to have significant growth due to the increasing geriatric population, prevalence of chronic diseases, and presence of a well-established healthcare system & reimbursement framework for clinical lab services. Moreover, key players focus on developing innovative tests. For instance, in July 2022, Abbott demonstrated diagnostic innovations to enhance patient care at the American Association for Clinical Chemistry (AACC) Clinical Lab expo. Leading clinical labs offer patients and healthcare professionals with crucial diagnostic information and are represented by the American Clinical Laboratory, a national trade group.

Key Companies & Market Share Insights

The key players operating in the industry are focusing on geographic expansion, partnerships, and strategic collaborations with other companies, particularly in emerging and economically favorable regions. For instance, in October 2022, Enzo Biochem, Inc. expanded its life sciences laboratory research facilities in Farmingdale, New York. Some of the prominent players operating in the global clinical laboratory service market include:

• QIAGEN

• Quest Diagnostics Inc.

• OPKO Health, Inc.

• Abbott

• Siemens Medical Solutions USA, Inc.

• NeoGenomics Laboratories

• Fresenius Medical Care

• ARUP Laboratories

• Sonic Healthcare

• Laboratory Corporation of America Holdings (LabCorp)

Clinical Laboratory Service Market Report Scope

Global Clinical Laboratory Service Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global clinical laboratory service market report on the basis oftest type, service provider, application, and region:

• Test Type Outlook (Revenue, USD Billion, 2018 - 2030)

  • Human & Tumor Genetics

  • Clinical Chemistry

  • Medical Microbiology & Cytology

  • Other Esoteric Tests

• Service Provider Outlook (Revenue, USD Billion, 2018 - 2030)

  • Hospital-based Laboratories

  • Stand-alone Laboratories

  • Clinic-based Laboratories

• Application Outlook (Revenue, USD Billion, 2018 - 2030)

  • Bioanalytical & Lab Chemistry Services

  • Toxicology Testing Services

  • Cell & Gene Therapy Related Services

  • Preclinical & Clinical Trial Related Services

  • Drug Discovery & Development Related Services

  • Other Clinical Laboratory Services

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Spain

    • Italy

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Colombia

    • Peru

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE